On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Investigational; FDA identifies retatrutide as an unapproved drug.
Three receptor targets
The molecule activates GIP, GLP-1, and glucagon receptors; receptor count alone cannot establish superiority over another treatment. [1]
What the evidence shows
Obesity research
A phase 2 trial enrolled 338 adults and followed weight change for 48 weeks. Retatrutide groups lost more weight than placebo; the highest studied group averaged 24.2% reduction. This is a group result, not a forecast for an individual. [1]
Trial product versus marketed vials
FDA states that retatrutide is not an ingredient of an approved drug. A research-vial label does not establish that its contents match a clinical trial product. [2]
What remains unknown
The cited trial does not establish safety of combinations with other incretin drugs or the identity of products sold outside research.
Safety
Tolerability and pulse
Gastrointestinal effects were common and dose-related in the phase 2 trial. Heart rate increased during treatment before declining later in follow-up. [1]
Studied route
The cited obesity trial used a subcutaneous research formulation. It does not validate an oral product with the same name. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does triple agonist mean three medicines mixed together?
No. In this study it describes one molecule acting at GIP, GLP-1, and glucagon receptors.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial2023 · Primary research · PubMed
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossFDA · Retatrutide and cagrilintide status
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.